Longitudinal data layer
A person's health as a timeline, not a series of visits. Standards-based, so it sits beside any record system. De-identified and governed from the first record.
We are treating cancer too late
The intelligence layer for cancer care.
BioSynova is building the clinical intelligence system behind a more continuous model of cancer care. It brings together longitudinal data, physician-guided models, and operational AI to help specialists support people before a diagnosis and long after treatment.
Clinical proof · BioNurture
The first physician-led practice on the system is live in Texas and Florida.
Precision oncology for the whole timeline of cancer.
Cancer care is often organized around diagnosis and treatment. BioSynova is being built to extend specialist expertise into the years before a diagnosis and the decades after treatment, with a clearer view of each person over time.
RiskSignalDiagnosisTreatmentSurvivorship
Today's system
Care centered on diagnosis and treatment
With BioSynova
Personalized risk assessment
Specialist-guided care
Long-term survivorship support
Physician-foundedAgent-nativeLongitudinal by designCompliance by architectureSpecialist-builtDecision support, never diagnosis
The thesis
We are treating cancer too late. We declare victory too soon. A specialist’s judgment belongs on both sides of treatment.
People have more access to tests, imaging, and health data, but results alone do not explain their individual cancer risk. After treatment, survivors can face fears of recurrence, lasting side effects, and unanswered questions between visits. Arisha saw both gaps in her own practice: people who needed a specialist before a diagnosis, and people who still needed one after treatment ended.
The future of oncology will not be defined only by new drugs. It will be defined by how early we begin to intervene, and how continuously. That takes a system, not a hero clinician. BioSynova is that system.
2M+
new cancer diagnoses in the United States each year
American Cancer Society18M+
people living with and after cancer, and the number is rising
ACS · NCIScarce
oncologist supply projected to fall short of demand through the next decade
ASCO workforce projections
Cancer is not an event
We know how to treat what we can see. The next challenge is seeing sooner.
Family history, genetics, lab results, imaging, and treatment history each tell part of a person’s story. BioSynova is being built to bring those records together over time, helping physicians interpret changes in context and study which patterns may matter for prevention and survivorship.
- 2018Family history documented
- 2020Lab results added
- 2023Imaging reviewed
- 2026Risk assessment updated
Illustrative timeline: a view of records over time, not a prediction of cancer.
Why now
Four curves are crossing at the same time.
More health data, new AI capabilities, and a growing need for long-term support create an opportunity to build cancer care around a specialist’s judgment.
Survivorship is a long chapter.
The end of treatment can begin years of questions about recurrence, treatment effects, and long-term health. Specialist support should extend into that chapter.
More testing needs more context.
People can access more tests than ever. Arisha’s point is simple: a result needs interpretation by someone who understands the person, the test’s limitations, and what to do next.
AI can support the work around care.
Operational AI can help organize information and coordinate workflows, giving physicians more time for the decisions and conversations that need them.
Specialist access is part of the care model.
BioNurture offers a concierge approach for people who want a specialist partner in cancer prevention and survivorship.
Architecture
Four layers. One flywheel.
The model begins with care. Longitudinal records and specialist review create a foundation for studying patterns in prevention and survivorship. The Cancer Resilience Index is being developed to explore which markers may inform cancer risk and recurrence risk over time. Operational AI supports the work around that care; clinical use of the model depends on validation.
Care→Data→Review→Index↺
Cancer Resilience Index™
A model in development to study prevention and survivorship markers over time. Its research goal is to better understand patterns associated with cancer risk and recurrence risk. Predictive performance is not yet established. Clinical use depends on validation and physician review.
BioQuantum™ agent layer
Carries the operational load of a specialty practice and of the company. Model-agnostic. Every action logged. Every clinical touchpoint routed to a licensed physician.
Clinical and member interface
Decision support for the physician, and a member portal that makes a specialist feel present between visits. The AI is infrastructure. The physician is the voice the patient hears.
Engineering principles
The technology operates. The judgment stays human.
01
Longitudinal first
The person over time is the unit of the system. Everything else reads from that.
02
Validated before deployed
Models and agents earn their way into clinical use. Clinician review is part of the release.
03
Model-agnostic
No single vendor is a dependency. The architecture outlives any one model.
04
Privacy by architecture
Governance is designed into the data layer, not applied to it afterward.
05
Observable by default
Every action is logged and attributable. Audit is a query, not a project.
06
Human in the loop, always
The system proposes. The physician decides.
Clinical proof
The first practice on the system is live.
BioNurture is the clinical proof of concept for the care model Arisha describes: access to a specialist before diagnosis and after treatment. Its concierge practice focuses on cancer prevention, survivorship, and blood health. BioSynova is being built as the clinical intelligence system behind that care, connecting information over time to support physician judgment.
- The regulatory architecture is built. Entity structure, management agreements, data rights and privacy framework designed with national health-law counsel before the first patient.
- The operating layer is running. Agentic workflows already carry the operational load for the company and the practice.
- The data flywheel starts on day one. Governance and the longitudinal model are in place before the first encounter.
- The playbook is repeatable. One practice proves it. The same platform opens every practice after it.
Physician-owned practices
Deliver the care
Hold the patient relationship and the medical record. Employ the clinicians. Make every clinical decision.
↑ Platform & management↓ De-identified data license
BioSynova, Inc.
Owns the system
Technology, models, data infrastructure, brands and operations. Earns a fixed platform and management fee today. Licenses the intelligence tomorrow.
Founder
Built by the specialist it serves.
Founder & Chief Executive Officer
Arisha Patel, MD, MBA
Arisha is a triple board-certified oncologist, hematologist, and internist. She practiced breast oncology at Stanford and led precision oncology trials at Genentech, where she worked with increasingly personalized approaches to cancer treatment. Back in the clinic, she saw a gap: that expertise was not reaching people early enough, or staying with them long enough after treatment.
She founded BioNurture to give people a specialist partner in prevention and survivorship. Drawing on her clinical experience and her MBA in AI and biomedical entrepreneurship from Carnegie Mellon, she is building BioSynova as the clinical intelligence system behind that care.
Founder perspectiveA specialist on your team before a diagnosis, and long after treatment.
Triple board-certifiedInternal Medicine, Medical Oncology, Hematology
GenentechFormer Senior Medical Director, Personalized Healthcare
StanfordFormer Adjunct Clinical Instructor, Oncology & Hematology
Carnegie MellonMBA, AI & Biomedical Entrepreneurship · NIH T32 physician-scientist
Published & presentedThe Lancet Oncology · Cancer Discovery · JCO Clinical Cancer Informatics · British Journal of Haematology · Cancer · ASCO · AACR · ASH
Build with us
Build the company you wished existed when you were on call.
We are assembling the founding team. Small, senior, and in the room with a founder who has run trials, seen patients, and already shipped an agentic operating layer. Greenfield architecture. Founder-level equity for founder-level roles. Remote-first.
Open now · Founding role
Founding Chief Technology Officer
Own the platform end to end: data layer, member app, clinical interface and the agent layer that runs the company. Take the Cancer Resilience Index from development into clinical use.
- Founding engineersApplied ML & data
- Clinical informatics & productEHR-native
- Oncologists & hematologistsClinical
- OperatorsClinic operations
Investors
Back the intelligence layer for a specialty that has none.
A physician-founded Delaware company with the first practice live, the operating layer running, the IP strategy set, and the structure built for a venture path. We are opening investor conversations now.
- A platform business, not a clinic. Platform and management fees today; licensing the intelligence tomorrow.
- A data asset that compounds. Specialist-curated longitudinal oncology data with the rights to use it.
- A category with no incumbent. Oncology is where concierge care matters most and exists least.
- Structured for scale and exit. Repeatable playbook, interoperable platform, IP held in the company.
What investors ask first
Straight answers.
What is in the investor overview?
The thesis and market, the platform architecture, the entity and IP structure, the operating model and unit economics, the roadmap with dates, the team and advisors, and the terms of the current round. Sent on request under NDA.
What does BioSynova own, and what does it not?
BioSynova, Inc. owns the technology, the models, the data infrastructure, the brands and the operating platform. It does not own or practice medicine. Care is delivered by independently owned, physician-led practices that BioSynova supports under management services agreements.
Where does revenue come from?
Platform and management fees from the practices on the system today. Licensing of the intelligence layer to practices and health systems as the model and the index move from validation into use.
Why a physician founder, and why this one?
Arisha brings clinical practice, precision oncology trials, and training in AI and biomedical entrepreneurship to the same problem. Her work as an oncologist, hematologist, and internist informs what the system needs to help physicians see, and which decisions must stay with them.
What happens after I inquire?
You hear from the founder directly, within two business days. No automated sequences.
Inquire
Tell us who you are. The founder reads every one.
Investors, candidates, clinicians, partners and press. One form, read by a person, answered within two business days.
Or write directlyhello@biosynova.com